shutterstock_1523551736_frantic00
Frantic00 / Shutterstock.com
25 August 2020Big PharmaRobert Stephen and Gareth Morgan

Why Santen ends Neurim-style SPCs

The July 9 Santen decision ( C-673/18) from the Court of Justice of the European Union (CJEU) resolves the issues that arose from the earlier Neurim decision ( C-130/11) issued by the same court. Essentially, and unusually, the CJEU reversed its own earlier decision.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.